Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.54 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.37 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.37 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.37 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.37 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | PPM1B | O75688 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2954476 | 1.00 | ACE (0.54) | ACEP2RX7AKR1C3AKR1C2ITGB1 | |
| SCHEMBL14486941 | 0.90 | ACE (0.44) | ACEITGB1ITGA5THRBATM | |
| SCHEMBL10434958 | 0.86 | ACE (0.48) | ACEATML3MBTL1KMT2AMEN1 | |
| SCHEMBL8445034 | 0.86 | ACE (0.48) | ACEATML3MBTL1KMT2AMEN1 | |
| SCHEMBL23201306 | 0.83 | ACE (0.53) | ACEP2RX7ITGB1ITGA5KMT2A | |
| SCHEMBL30204217 | 0.83 | ACE (0.53) | ACEP2RX7ITGB1ITGA5KMT2A | |
| SCHEMBL3364315 | 0.80 | ACE (0.42) | ACEL3MBTL1KMT2AALDH1A1TSHR | |
| SCHEMBL13433707 | 0.80 | ACE (0.42) | ACEL3MBTL1KMT2AALDH1A1TSHR | |
| SCHEMBL12306682 | 0.80 | P2RX7 (0.38) | ACEP2RX7THRBKMT2AGAA | |
| SCHEMBL7397668 | 0.79 | AKR1C3 (0.39) | ACEAKR1C3AKR1C2THRBATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260008787-A1 | FUSED RING KRAS INHIBITORS FOR TREATING DISEASE | BLOSSOMHILL THERAPEUTICS INC (US) | 2026-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260008787-A1 | FUSED RING KRAS INHIBITORS FOR TREATING DISEASE | KRAS, NRAS, HRAS | ACE 2003/4885P2RX7 3895/4885AKR1C3 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.